Neurocrine Biosciences, Inc. (NBIX) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Neurocrine Biosciences, Inc. (NBIX) closed at USD 135.91 on 2026-10-14, a change of -7.8 % over the past year, with a market capitalization of USD 13.92B.

Neurocrine Biosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Neurocrine Biosciences, Inc. key figures

Previous close

USD 135.91 (2026-10-14)

1-year change

-7.8 %

Market cap

USD 13.92B

Enterprise value

USD 13.99B

P/E ratio (trailing)

19.82

P/E ratio (forward)

11.46

EPS (trailing)

6.91

EPS (forward)

11.95

PEG ratio

0.28

Price to book

3.77

Revenue growth

39.5 %

Earnings growth

31.1 %

Dividend per share (trailing)

0.00

Short ratio

4.67

Employees

2,500

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Neurocrine Biosciences, Inc. and compare it with other stocks.